GSK 9027Glucocorticoid receptor agonist CAS# 1229096-88-1 |
2D Structure
- Bromodomain Inhibitor, (+)-JQ1
Catalog No.:BCC1132
CAS No.:1268524-70-4
- (-)-JQ1
Catalog No.:BCC3603
CAS No.:1268524-71-5
- MS436
Catalog No.:BCC4037
CAS No.:1395084-25-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1229096-88-1 | SDF | Download SDF |
PubChem ID | 24882669 | Appearance | Powder |
Formula | C27H19F4N3O2S | M.Wt | 525.52 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO | ||
Chemical Name | N-[4-[1-(4-fluorophenyl)indazol-5-yl]-3-(trifluoromethyl)phenyl]-1-phenylmethanesulfonamide | ||
SMILES | C1=CC=C(C=C1)CS(=O)(=O)NC2=CC(=C(C=C2)C3=CC4=C(C=C3)N(N=C4)C5=CC=C(C=C5)F)C(F)(F)F | ||
Standard InChIKey | DXBJGDVBQPEMOB-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C27H19F4N3O2S/c28-21-7-10-23(11-8-21)34-26-13-6-19(14-20(26)16-32-34)24-12-9-22(15-25(24)27(29,30)31)33-37(35,36)17-18-4-2-1-3-5-18/h1-16,33H,17H2 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Glucocorticoid receptor agonist (pIC50 = 8). Inhibits production of the proinflammatory mediator IL-6 in vivo. |
GSK 9027 Dilution Calculator
GSK 9027 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 1.9029 mL | 9.5144 mL | 19.0288 mL | 38.0575 mL | 47.5719 mL |
5 mM | 0.3806 mL | 1.9029 mL | 3.8058 mL | 7.6115 mL | 9.5144 mL |
10 mM | 0.1903 mL | 0.9514 mL | 1.9029 mL | 3.8058 mL | 4.7572 mL |
50 mM | 0.0381 mL | 0.1903 mL | 0.3806 mL | 0.7612 mL | 0.9514 mL |
100 mM | 0.019 mL | 0.0951 mL | 0.1903 mL | 0.3806 mL | 0.4757 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Tatarinoid A
Catalog No.:BCN6119
CAS No.:1229005-35-9
- 12-Demethylneocaesalpin F
Catalog No.:BCN6410
CAS No.:1228964-10-0
- MLN0905
Catalog No.:BCC3961
CAS No.:1228960-69-7
- Ziprasidone HCl
Catalog No.:BCC2511
CAS No.:122883-93-6
- Mps1-IN-2
Catalog No.:BCC4153
CAS No.:1228817-38-6
- 2-Desoxy-4-epi-pulchellin
Catalog No.:BCN6118
CAS No.:122872-03-1
- AM-095 free base
Catalog No.:BCC1352
CAS No.:1228690-36-5
- AM966
Catalog No.:BCC1355
CAS No.:1228690-19-4
- TAK-632
Catalog No.:BCC3639
CAS No.:1228591-30-7
- GS-9620
Catalog No.:BCC1602
CAS No.:1228585-88-3
- Panaxyne
Catalog No.:BCN6462
CAS No.:122855-49-6
- Alosetron Hydrochloride
Catalog No.:BCC1344
CAS No.:122852-69-1
- 3-O-Acetylandrostenone hydrazone
Catalog No.:BCC8637
CAS No.:122914-94-7
- Edoxaban tosylate monohydrate
Catalog No.:BCC1545
CAS No.:1229194-11-9
- GS-9973
Catalog No.:BCC5278
CAS No.:1229208-44-9
- C 21
Catalog No.:BCC8013
CAS No.:1229236-78-5
- LY2784544
Catalog No.:BCC2200
CAS No.:1229236-86-5
- Fmoc-L-Beta-Homoproline
Catalog No.:BCN8087
CAS No.:193693-60-6
- N-(3-Methoxybenzyl)palmitamide
Catalog No.:BCN8086
CAS No.:847361-96-0
- XE 991 dihydrochloride
Catalog No.:BCC7232
CAS No.:122955-13-9
- URMC-099
Catalog No.:BCC5563
CAS No.:1229582-33-5
- 6'-O-Galloyl paeoniflorin
Catalog No.:BCN2941
CAS No.:122965-41-7
- HA 130
Catalog No.:BCC7884
CAS No.:1229652-21-4
- RG7388
Catalog No.:BCC1895
CAS No.:1229705-06-9
Structure guided design of 5-arylindazole glucocorticoid receptor agonists and antagonists.[Pubmed:20469868]
J Med Chem. 2010 Jun 10;53(11):4531-44.
Glucocorticoid receptor (GR) agonists have been used for more than half a century as the most effective treatment of acute and chronic inflammatory conditions despite serious side effects that accompany their extended use that include glucose intolerance, muscle wasting, skin thinning, and osteoporosis. As a starting point for the identification of GR ligands with an improved therapeutic index, we wished to discover selective nonsteroidal GR agonists and antagonists with simplified structure compared to known GR ligands to serve as starting points for the optimization of dissociated GR modulators. To do so, we selected multiple chemical series by structure guided docking studies and evaluated GR agonist activity. From these efforts we identified 5-arylindazole compounds that showed moderate binding to the glucocorticoid receptor (GR) with clear opportunities for further development. Structure guided optimization was used to design arrays that led to potent GR agonists and antagonists. Several in vitro and in vivo experiments were utilized to demonstrate that GR agonist 23a (GSK9027) had a profile similar to that of a classical steroidal GR agonist.